Carregant...
Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia
Ponatinib is associated with cardiovascular adverse events (CAEs), and its frequency in the real world is limited. In this retrospective study, we examined the survival outcomes and associated toxicities in 78 consecutive ponatinib-treated patients with chronic myeloid leukemia (CML) at the Moffitt...
Guardat en:
| Publicat a: | Blood Adv |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7013263/ https://ncbi.nlm.nih.gov/pubmed/32045474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000268 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|